Russell Investments Group Ltd. decreased its position in shares of Luminex Co. (NASDAQ:LMNX) by 5.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 271,397 shares of the medical instruments supplier’s stock after selling 15,758 shares during the quarter. Russell Investments Group Ltd.’s holdings in Luminex were worth $5,538,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Neuberger Berman Group LLC boosted its holdings in shares of Luminex by 11.0% during the first quarter. Neuberger Berman Group LLC now owns 1,006,558 shares of the medical instruments supplier’s stock valued at $23,162,000 after acquiring an additional 99,655 shares during the period. Investment Management of Virginia LLC raised its stake in shares of Luminex by 4.7% during the second quarter. Investment Management of Virginia LLC now owns 953,295 shares of the medical instruments supplier’s stock valued at $19,676,000 after purchasing an additional 42,614 shares in the last quarter. Elk Creek Partners LLC bought a new stake in shares of Luminex during the first quarter valued at about $7,105,000. Kennedy Capital Management Inc. bought a new stake in shares of Luminex during the first quarter valued at about $6,162,000. Finally, Marshall Wace LLP raised its stake in shares of Luminex by 3,439.2% during the first quarter. Marshall Wace LLP now owns 195,680 shares of the medical instruments supplier’s stock valued at $4,503,000 after purchasing an additional 190,151 shares in the last quarter. 79.78% of the stock is owned by institutional investors.

Shares of NASDAQ LMNX traded up $0.01 during midday trading on Friday, reaching $22.55. 3,055 shares of the company traded hands, compared to its average volume of 142,740. Luminex Co. has a 52 week low of $19.41 and a 52 week high of $30.73. The stock has a 50-day moving average price of $20.71 and a 200 day moving average price of $21.87. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.74 and a quick ratio of 2.45. The company has a market cap of $932.47 million, a price-to-earnings ratio of 47.00 and a beta of 0.78.

Luminex (NASDAQ:LMNX) last issued its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.09). Luminex had a negative net margin of 0.80% and a negative return on equity of 0.78%. The company had revenue of $83.06 million for the quarter, compared to the consensus estimate of $81.61 million. During the same quarter in the prior year, the firm earned $0.15 earnings per share. Luminex’s revenue for the quarter was up 4.4% compared to the same quarter last year. As a group, analysts expect that Luminex Co. will post -0.16 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 17th. Shareholders of record on Thursday, September 26th will be given a $0.09 dividend. The ex-dividend date of this dividend is Wednesday, September 25th. This is a boost from Luminex’s previous quarterly dividend of $0.06. This represents a $0.36 annualized dividend and a yield of 1.60%. Luminex’s payout ratio is 50.00%.

In other Luminex news, CEO Nachum Shamir purchased 5,000 shares of the company’s stock in a transaction on Monday, August 26th. The shares were purchased at an average cost of $19.71 per share, for a total transaction of $98,550.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 8.70% of the stock is currently owned by insiders.

A number of equities research analysts recently weighed in on the stock. ValuEngine upgraded shares of Luminex from a “buy” rating to a “strong-buy” rating in a research note on Thursday. BidaskClub cut shares of Luminex from a “hold” rating to a “sell” rating in a research note on Friday, September 6th. Finally, Zacks Investment Research upgraded shares of Luminex from a “strong sell” rating to a “hold” rating and set a $17.00 price objective on the stock in a research note on Tuesday, July 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $25.00.

Luminex Company Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.

See Also: Trading Penny Stocks

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.